Tourmaline Bio, Inc.
Tourmaline Bio, Inc.（TRML）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · TRML · 截至 2025年9月30日
股东结构概览
141
机构持有人数
▲ 34 vs Q2
$1.04B
机构持仓总市值
▲ $650.37M vs Q2
25.69M
总流通股
freeFloat 65.41%
21.64M
13F 申报持股数
▼ 2.42M vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
TRML 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
AVORO CAPITAL ADVISORS LLC biological products, (no diagnostic substances) | 2.56M | 9.92% | 9.92% | $122.23B | Nov 14, 2025 | — held |
QVT FINANCIAL LP biological products, (no diagnostic substances) | 2.15M | 8.37% | 8.37% | $103.06B | Nov 14, 2025 | — held |
BLACKROCK, INC. biological products, (no diagnostic substances) | 1.52M | 5.89% | 5.89% | $72.60B | Nov 12, 2025 | ▼ 116.2K |
TCG CROSSOVER MANAGEMENT, LLC biological products, (no diagnostic substances) | 1.31M | 5.09% | 5.09% | $62.74B | Nov 17, 2025 | ▼ 165.8K |
PFIZER INC biological products, (no diagnostic substances) | 1.27M | 4.94% | 4.94% | $60.85B | Nov 13, 2025 | — held |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 1.17M | 4.53% | 4.53% | $55.75B | Nov 7, 2025 | ▼ 41.4K |
FIL LTD biological products, (no diagnostic substances) | 1.03M | 3.99% | 3.99% | $49.15B | Nov 13, 2025 | NEW |
MAGNETAR FINANCIAL LLC biological products, (no diagnostic substances) | 966.1K | 3.75% | 3.75% | $46.21B | Nov 13, 2025 | NEW |
QIMING U.S. VENTURES MANAGEMENT, LLC biological products, (no diagnostic substances) | 741.7K | 2.88% | 2.88% | $35.48B | Nov 10, 2025 | — held |
FIRST TRUST CAPITAL MANAGEMENT L.P. biological products, (no diagnostic substances) | 695.8K | 2.70% | 2.70% | $33.28B | Nov 17, 2025 | NEW |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
8
增持
+1.09M 股19
新建仓
首次建仓17
减持
−1.34M 股0
清仓
完全退出净股数变化（前50家）
248.0K
+1.09M / −1.34M
净新增持仓人
+10
新建 19 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
TRML 内幕交易记录
数据来源：SEC Form 4
2
买入笔数
53
卖出笔数
0.04
买卖比
$4M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
SIEGALL CLAY B director | Oct 28, 2025 | D-Return | 16,800 | $18.73 | $314.7K | 0 | Form 4 ↗ |
SIEGALL CLAY B director | Oct 28, 2025 | D-Return | 15,000 | $13.91 | $208.7K | 0 | Form 4 ↗ |
SIEGALL CLAY B director | Oct 28, 2025 | D-Return | 20,000 | $18.55 | $371.0K | 0 | Form 4 ↗ |
Thiara Parvinder director | Oct 28, 2025 | D-Return | 16,800 | $18.73 | $314.7K | 0 | Form 4 ↗ |
Thiara Parvinder director | Oct 28, 2025 | U-Tender | 83,782 | $48.00 | $4.02M | 0 | Form 4 ↗ |
Thiara Parvinder director | Oct 28, 2025 | D-Return | 10,000 | $9.46 | $94.6K | 0 | Form 4 ↗ |
Thiara Parvinder director | Oct 28, 2025 | D-Return | 10,000 | $13.91 | $139.1K | 0 | Form 4 ↗ |
Srivastava Sapna director | Oct 28, 2025 | D-Return | 20,000 | $9.46 | $189.2K | 0 | Form 4 ↗ |
Srivastava Sapna director | Oct 28, 2025 | D-Return | 16,800 | $18.73 | $314.7K | 0 | Form 4 ↗ |
Srivastava Sapna director | Oct 28, 2025 | D-Return | 10,000 | $13.91 | $139.1K | 0 | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Tourmaline Bio, Inc.（TRML）主要由机构投资者持有，机构持股比例约为 84.2%。公司内部人员持股约 34.59%，散户及公众持股约占剩余的 0.00%。
Tourmaline Bio, Inc. 最大机构股东为 AVORO CAPITAL ADVISORS LLC，截至 September 30, 2025 持有约 2.56 million 股，占总流通股的 9.92%。
目前共有 141 家机构持有 TRML 股票，合计持仓市值约 $1.04 billion，数据来源为最新 SEC 13F 申报。
常见问题
TRML ownershipTourmaline Bio, Inc.（TRML）主要由机构投资者持有，机构持股约 84.2%。最大股东为 AVORO CAPITAL ADVISORS LLC，持股比例 9.92%。内部人员持股约 34.59%。数据来源 SEC Form 13F，截至 September 30, 2025。